Portfolio Design Labs LLC Buys 26 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Portfolio Design Labs LLC boosted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 9.4% in the third quarter, HoldingsChannel reports. The firm owned 302 shares of the biopharmaceutical company’s stock after acquiring an additional 26 shares during the period. Portfolio Design Labs LLC’s holdings in Regeneron Pharmaceuticals were worth $317,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in REGN. International Assets Investment Management LLC grew its stake in Regeneron Pharmaceuticals by 86,013.3% in the third quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock valued at $926,078,000 after acquiring an additional 879,916 shares during the period. Price T Rowe Associates Inc. MD grew its stake in Regeneron Pharmaceuticals by 25.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 902,613 shares of the biopharmaceutical company’s stock valued at $868,757,000 after acquiring an additional 184,561 shares during the period. Swedbank AB acquired a new position in Regeneron Pharmaceuticals in the first quarter valued at about $129,257,000. Epoch Investment Partners Inc. acquired a new position in Regeneron Pharmaceuticals in the first quarter valued at about $99,667,000. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its stake in Regeneron Pharmaceuticals by 23.8% in the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 500,274 shares of the biopharmaceutical company’s stock valued at $525,804,000 after acquiring an additional 96,266 shares during the period. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Down 0.2 %

Shares of NASDAQ:REGN opened at $743.35 on Thursday. The firm has a market cap of $81.69 billion, a P/E ratio of 18.40, a P/E/G ratio of 2.81 and a beta of 0.15. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 12-month low of $736.01 and a 12-month high of $1,211.20. The business has a fifty day simple moving average of $961.76 and a 200 day simple moving average of $1,030.14.

Analyst Upgrades and Downgrades

REGN has been the subject of several recent research reports. JPMorgan Chase & Co. reduced their price objective on Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating for the company in a research report on Thursday, October 24th. Leerink Partners reaffirmed a “market perform” rating and set a $1,077.00 price objective (down from $1,175.00) on shares of Regeneron Pharmaceuticals in a research report on Tuesday, September 24th. StockNews.com cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 4th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $1,015.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Wednesday, October 23rd. Finally, Oppenheimer dropped their target price on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a report on Wednesday, November 6th. One analyst has rated the stock with a sell rating, four have issued a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $1,099.55.

Insider Buying and Selling

In other news, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the transaction, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. This trade represents a 27.07 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 7.48% of the stock is owned by corporate insiders.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.